| Serial Number | 97728325 |
| Word Mark | ETHERNA |
| Filing Date | Thursday, December 22, 2022 |
| Status | 730 - FIRST EXTENSION - GRANTED |
| Status Date | Tuesday, August 13, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, January 2, 2024 |
| Goods and Services | Custom manufacture of pharmaceutical and medical preparations; custom manufacture of mRNA molecules; custom manufacture of mRNA molecules formulated in lipid nanoparticles; custom manufacture of mRNA for use in vaccines, cell therapy, gene editing, protein replacement, and antibodies; provision of information, advice and consultancy services relating to all of the aforesaid |
| Goods and Services | Vaccines; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for preventing and treating viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; mRNA-based therapeutics and therapeutic agents for in prevention and treatment of viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; lipid nanoparticles for pharmaceutical, medical or diagnostic purposes for preventing and treating viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; lipid nanoparticles for drug delivery sold as an integral component of drugs in the nature of pharmaceutical preparations for preventing and treating viruses, medical disorders, and diseases, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations, namely, messenger RNA and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells for preventing and treating viruses, medical disorders, and diseases, namely, viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders |
| Goods and Services | Biological preparations for scientific and research purposes for boosting cells in the immune system for improved therapies; biological preparations for scientific and research purposes, namely, a mRNA-based composition for enhancing immunities; biological preparations in the nature of genetically modified cells and vectors for scientific and research purposes; biological and chemical reagents including complexes of these molecules for research purposes, for clinical research, clinical chemistry, clinical trials, scientific research, medical research, laboratory research, and for industrial use, namely, for use in the manufacture of pharmaceuticals |
| Goods and Services | Scientific research and development; pharmaceutical research and development services; medical research and development services; scientific, pharmaceutical, and medical research and development in the field of mRNA therapeutics; scientific, pharmaceutical, and medical research and development in the field of proprietary lipids and lipid nanoparticle formulations for the delivery of mRNA therapeutics for the treatment of various medical disorders, cancer, and infectious diseases |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, January 19, 2023 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, January 19, 2023 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, January 19, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, January 19, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | eTheRNA immunotherapies NV |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Niel 2845 BE |
| Party Name | eTheRNA immunotherapies NV |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Niel 2845 BE |
| Event Date | Event Description |
| Monday, December 26, 2022 | NEW APPLICATION ENTERED |
| Thursday, January 19, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, September 22, 2023 | ASSIGNED TO EXAMINER |
| Friday, October 6, 2023 | NON-FINAL ACTION WRITTEN |
| Friday, October 6, 2023 | NON-FINAL ACTION E-MAILED |
| Friday, October 6, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, October 26, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, October 26, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, October 26, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, November 28, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, December 13, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, January 2, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, January 2, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, February 27, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, August 13, 2024 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, August 13, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, August 13, 2024 | SOU EXTENSION 1 FILED |
| Tuesday, August 13, 2024 | SOU EXTENSION 1 GRANTED |
| Friday, August 16, 2024 | TEAS STATEMENT OF USE RECEIVED |